Parkinson’s disease affects more than 10 million people worldwide. Discover its causes, symptoms, and the latest innovations ...

Neuron23® Inc., a clinical-stage biotechnology company focused on developing precision medicines for genetically defined ...

Parkinson's disease is most often seen in those over 60. ... A person who is diagnosed without cause has what is called idiopathic Parkinson's disease, according to Healthline.

Parkinson's disease is the second most common neurodegenerative disorder, affecting 2% to 3% of adults aged 65 or older. The disorder is not fatal, but it's incurable and can severely impact your ...

A large longitudinal study found that pesticide exposure and caffeinated soda intake were linked to more severe motor ...

In the NEULARK trial, patients with early-stage LRRK2-driven Parkinson's disease will receive Neuron23's NEU-411 or a placebo.

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug ...

Parkinson's disease symptoms usually begin unilaterally. Wearing-off effect: The tendency, following long-term levodopa treatment, for each dose of the drug to be effective for shorter periods of ...

Restricting the analysis to idiopathic Parkinson's disease showed a comparably strong association with autism (RR 3.53, 95% CI 1.86-6.70), Yin and co-authors said.